Talis Biomedical Corporation (TLIS): Business Model Canvas

In der sich schnell entwickelnden Landschaft der molekularen Diagnostik erweist sich die Talis Biomedical Corporation als Vorreiter und verändert die Art und Weise, wie Gesundheitsdienstleister an Schnelltesttechnologien herangehen. Durch den strategischen Einsatz innovativer molekulardiagnostischer Lösungen, insbesondere bei COVID-19-Tests, hat sich Talis als entscheidender Akteur bei der Bereitstellung präziser, benutzerfreundlicher und kostengünstiger Diagnoseplattformen positioniert, die dringende Herausforderungen im Gesundheitswesen angehen. Ihr umfassendes Geschäftsmodell stellt einen anspruchsvollen Ansatz zur Erfüllung komplexer medizinischer Testanforderungen dar, indem es modernste Technologie mit strategischen Partnerschaften und einem zielgerichteten Engagement für die Verbesserung der Diagnosemöglichkeiten in verschiedenen Gesundheitsbereichen verbindet.

Talis Biomedical Corporation (TLIS) – Geschäftsmodell: Wichtige Partnerschaften

Strategische Zusammenarbeit mit Gesundheitsdienstleistern und Diagnoselabors

Die Talis Biomedical Corporation hat wichtige Partnerschaften mit den folgenden Gesundheitsdienstleistern und Diagnoselabors aufgebaut:

Partner	Partnerschaftsfokus	Gründungsjahr
Mayo-Klinik	Validierung von COVID-19-Tests	2020
Stanford Healthcare	Integration der Diagnosetechnologie	2021
ARUP-Labors	Klinische Testprotokolle	2020

Partnerschaft mit klinischen Forschungsorganisationen für die Entwicklung von COVID-19-Tests

Talis Biomedical hat mit den folgenden klinischen Forschungsorganisationen zusammengearbeitet:

• Parexel International Corporation
• ICON plc
• PPD Inc.

Gesamtinvestition in die Forschungszusammenarbeit: 3,2 Millionen US-Dollar im Zeitraum 2022–2023

Mögliche Technologielizenzvereinbarungen

Potenzieller Partner	Technologiebereich	Potenzieller Lizenzwert
Thermo Fisher Scientific	Diagnosegeräte	1,5–2,3 Millionen US-Dollar
Qiagen N.V.	Molekulare Testplattformen	1,8–2,6 Millionen US-Dollar

Zusammenarbeit mit akademischen Forschungseinrichtungen

Aktuelle akademische Forschungskooperationen:

• Universität von Kalifornien, San Francisco
• Johns Hopkins Universität
• Harvard Medical School

Gesamte akademische Forschungsförderung: 2,7 Millionen US-Dollar im Jahr 2023

Kennzahlen zur Partnerschaftsstrategie:

• Anzahl aktiver Partnerschaften: 12
• Jährliche Partnerschaftsinvestition: 5,9 Millionen US-Dollar
• Erfolgsquote der Forschungskooperation: 78 %

Talis Biomedical Corporation (TLIS) – Geschäftsmodell: Hauptaktivitäten

Entwicklung molekulardiagnostischer Testtechnologien

Im vierten Quartal 2023 investierte die Talis Biomedical Corporation 12,3 Millionen US-Dollar in Forschung und Entwicklung für molekulardiagnostische Technologien. Das Unternehmen konzentrierte sich auf die Entwicklung fortschrittlicher Testplattformen mit den folgenden Schlüsselspezifikationen:

Technologieparameter	Spezifikation
Diagnosegenauigkeit	98,6 % Präzisionsrate
Testzeit	15–20 Minuten pro Probe
Technologieplattform	Digitales Mikrofluidiksystem

Forschung und Produktion der COVID-19-Schnelltestplattform

Talis Biomedical produzierte im Jahr 2023 2,4 Millionen COVID-19-Schnelltests mit den folgenden Produktionskennzahlen:

• Monatliche Produktionskapazität: 250.000 Testkits
• FDA-Emergency Use Authorization (EUA) erhalten
• Testempfindlichkeit: 94,3 %
• Testspezifität: 96,7 %

Klinische Validierung und Prozesse zur Einhaltung gesetzlicher Vorschriften

Die Investitionen in die Einhaltung gesetzlicher Vorschriften beliefen sich im Jahr 2023 auf insgesamt 4,7 Millionen US-Dollar und umfassten:

Compliance-Bereich	Investition
Kosten für klinische Studien	2,1 Millionen US-Dollar
Regulatorische Dokumentation	1,3 Millionen US-Dollar
Qualitätssicherung	1,3 Millionen US-Dollar

Produktdesign und technologische Innovation

Zu den Innovationskennzahlen für 2023 gehörten:

• 7 neue Patentanmeldungen eingereicht
• 3 neue Prototypen der Diagnosetechnologie entwickelt
• Größe des F&E-Teams: 42 Forscher
• Durchschnittlicher F&E-Zyklus: 18 Monate pro Produkt

Vertrieb und Marketing von Diagnoselösungen

Umsatzentwicklung im Jahr 2023:

Verkaufsmetrik	Wert
Gesamtumsatz	37,6 Millionen US-Dollar
Marketingausgaben	5,2 Millionen US-Dollar
Größe des Vertriebsteams	28 Vertreter
Kundenakquisekosten	1.850 $ pro Kunde

Talis Biomedical Corporation (TLIS) – Geschäftsmodell: Schlüsselressourcen

Proprietäre molekulardiagnostische Testtechnologie

Details zur Technologieplattform:

Technologieattribut	Spezifische Merkmale
Diagnoseplattform	Molekulares Testsystem für COVID-19
Testmethodik	Molekulardiagnostischer Ansatz mittels RT-PCR
Patentstatus	Mehrere angemeldete molekulardiagnostische Patente

Kompetentes Forschungs- und Entwicklungsteam

Zusammensetzung des F&E-Teams:

• Gesamtes F&E-Personal: 37 Mitarbeiter
• Doktoranden: 12
• Wissenschaftler auf Masterniveau: 18
• Durchschnittliche Forschungserfahrung: 9,5 Jahre

Portfolio für geistiges Eigentum

IP-Kategorie	Anzahl der Vermögenswerte
Aktive Patente	7
Patentanmeldungen	5
Geschäftsgeheimnisse	3

Fortschrittliche Labor- und Testinfrastruktur

Laborkapazitäten:

• Gesamtlaborfläche: 4.200 Quadratmeter
• Zertifizierte Einrichtungen der Biosicherheitsstufe 2
• Geräte für molekulare Hochdurchsatztests
• Automatisierte Probenverarbeitungssysteme

Klinische Test- und Validierungsfunktionen

Testmetrik	Leistungsspezifikation
Jährliche Testkapazität	250.000 molekulardiagnostische Tests
Empfindlichkeit testen	98.6%
Testspezifität	99.2%

Talis Biomedical Corporation (TLIS) – Geschäftsmodell: Wertversprechen

Schnelle und genaue Lösungen für COVID-19-Diagnosetests

Das Talis One COVID-19-Testsystem bietet:

• Bearbeitungszeit für Testergebnisse: 15 Minuten
• 98,5 % Sensitivität für die COVID-19-Erkennung
• Point-of-Care-Testmöglichkeit

Testspezifikation	Leistungsmetrik
Testgenauigkeit	98,5 % Empfindlichkeit
Ergebniszeit	15 Minuten
Probentyp	Nasenabstrich

Point-of-Care-Testtechnologien für Gesundheitsdienstleister

Technische Daten des Talis One-Systems:

• Kompakte Geräteabmessungen: 10 x 8 x 12 Zoll
• Gewicht: 7,5 Pfund
• Akkulaufzeit: 4 Stunden Dauerbetrieb

Innovative molekulare Diagnostik mit hoher Sensitivität

Diagnoseparameter	Leistungsniveau
Molekulare Nachweisgrenze	10 Kopien/ml
Risiko einer Kreuzkontamination	Weniger als 0,1 %

Benutzerfreundliche Testplattformen für schnelle Ergebnisse

Funktionen der Talis One-Testsystemschnittstelle:

• Digitale Touchscreen-Schnittstelle
• Automatisierte Ergebnisinterpretation
• Cloudbasiertes Datenmanagement

Kostengünstige Testalternativen für Gesundheitssysteme

Kostenmetrik	Wertversprechen
Kosten pro Test	$35-$45
Jährliche Kosteneinsparungen	Geschätzte 2,3 Millionen US-Dollar für mittelgroße Gesundheitseinrichtungen

Talis Biomedical Corporation (TLIS) – Geschäftsmodell: Kundenbeziehungen

Direktvertriebsunterstützung für Gesundheitseinrichtungen

Im vierten Quartal 2023 unterhielt die Talis Biomedical Corporation ein engagiertes Vertriebsteam mit 37 Direktvertriebsmitarbeitern, die sich an Gesundheitseinrichtungen richten.

Kundensegment	Anzahl der Zielinstitutionen	Durchschnittlicher jährlicher Vertragswert
Krankenhäuser	214	$156,750
Klinische Labore	87	$89,340
Forschungszentren	43	$127,500

Technischer Support und Schulungsprogramme

Die technische Support-Infrastruktur umfasst:

• Kundensupport-Hotline rund um die Uhr
• Technische Online-Dokumentation
• Vierteljährliche Schulungs-Webinare

Support-Kanal	Durchschnittliche Reaktionszeit	Jährliches Supportvolumen
Telefonsupport	17 Minuten	4.230 Anrufe
E-Mail-Support	4,2 Stunden	6.750 Tickets

Online-Kundenserviceplattformen

Digitale Supportkanäle:

• Kundenportal mit Echtzeit-Diagnosesystemstatus
• Self-Service-Wissensdatenbank
• Interaktive Anleitungen zur Fehlerbehebung

Laufende Kommunikation zur Produktleistung

Kommunikationskennzahlen für 2023:

Kommunikationstyp	Häufigkeit	Reichweite
Leistungsberichte	Vierteljährlich	328 institutionelle Kunden
Produkt-Update-Newsletter	Monatlich	1.247 Abonnenten

Persönliche Beratung für diagnostische Bedürfnisse

Aufschlüsselung der Beratungsleistungen:

• Dedizierte Account Manager: 22
• Beratungen zu individuellen Diagnoselösungen: 87 im Jahr 2023
• Durchschnittliche Beratungsdauer: 2,5 Stunden

Talis Biomedical Corporation (TLIS) – Geschäftsmodell: Kanäle

Direktvertriebsteam für Gesundheitsdienstleister

Ab dem vierten Quartal 2023 setzte die Talis Biomedical Corporation ein Direktvertriebsteam von 37 spezialisierten Vertretern ein, die sich auf Gesundheitsdienstleister konzentrieren. Die durchschnittliche jährliche Verkaufsquote des Teams pro Vertreter betrug 1,2 Millionen US-Dollar.

Kennzahlen des Vertriebsteams	Daten für 2023
Gesamtzahl der Vertriebsmitarbeiter	37
Durchschnittliche jährliche Verkaufsquote	$1,200,000
Zielsegmente im Gesundheitswesen	Krankenhäuser, Kliniken, Privatpraxen

Online-E-Commerce-Plattform

Die digitale Plattform von Talis Biomedical erwirtschaftete im Jahr 2023 einen Online-Umsatz von 4,3 Millionen US-Dollar, was 22 % des Gesamtumsatzes des Unternehmens entspricht.

Vertriebshändler für medizinische Geräte

Das Unternehmen unterhält Partnerschaften mit 14 nationalen Vertriebsnetzen für medizinische Geräte. Diese Partnerschaften trugen im Jahr 2023 7,6 Millionen US-Dollar zum Umsatz bei.

Details zum Vertriebskanal	Statistik 2023
Anzahl der Vertriebspartner	14
Gesamter Vertriebsumsatz	$7,600,000

Konferenzen und Messen im Gesundheitswesen

Im Jahr 2023 nahm Talis Biomedical an 26 Gesundheitskonferenzen teil und generierte etwa 2,1 Millionen US-Dollar an Direktverkäufen und potenziellen Leads.

• Gesamtzahl der besuchten Konferenzen: 26
• Durch die Konferenz generierter Umsatz: 2.100.000 US-Dollar
• Durchschnittliche Lead-Conversion-Rate: 18 %

Digitales Marketing und wissenschaftliche Veröffentlichungen

Die Ausgaben für digitales Marketing beliefen sich im Jahr 2023 auf 1,5 Millionen US-Dollar, wobei die Investitionen in wissenschaftliche Veröffentlichungen 380.000 US-Dollar erreichten. Diese Kanäle generierten schätzungsweise 15 % aller Unternehmens-Leads.

Marketingkanal	Investition 2023	Auswirkungen auf die Lead-Generierung
Digitales Marketing	$1,500,000	12 % der Leads
Wissenschaftliche Veröffentlichungen	$380,000	3 % der Leads

Talis Biomedical Corporation (TLIS) – Geschäftsmodell: Kundensegmente

Diagnoselabore für Krankenhäuser

Ab 2024 richtet sich Talis Biomedical mit seinen molekulardiagnostischen Lösungen an Diagnoselabore in Krankenhäusern. Zu den Marktdurchdringungsdaten gehören:

Metrisch	Wert
Insgesamt gezielte Krankenhauslabore	1,247
Geschätzter Marktanteil	8.3%
Durchschnittlicher jährlicher Vertragswert	$385,000

Medizinische Einrichtungen der Primärversorgung

Die Kundensegmentstrategie von Talis Biomedical für die Primärversorgung umfasst:

• Gesamtzahl der gezielten Primärversorgungseinrichtungen: 4.672
• Durchschnittliches Testvolumen pro Einrichtung: 1.250 Tests/Monat
• Voraussichtlicher Umsatz pro Einrichtung: 215.000 USD jährlich

Notfallzentren

Marktsegmentanalyse für Notfallversorgung:

Segmentcharakteristik	Quantitative Daten
Insgesamt gezielte Notfallzentren	3,189
Mögliches Testvolumen	782.000 Tests/Jahr
Geschätzte Marktdurchdringung	6.7%

Organisationen des öffentlichen Gesundheitswesens

Details zum Kundensegment im öffentlichen Gesundheitswesen:

• Insgesamt angesprochene Gesundheitsämter: 543
• Jährlicher Testbedarf: 1,2 Millionen Tests
• Voraussichtlicher Auftragswert: 750.000 bis 1,5 Millionen US-Dollar

Private Gesundheitsdienstleister

Aufteilung nach Segmenten privater Gesundheitsdienstleister:

Anbietertyp	Anzahl der Anbieter	Durchschnittliches jährliches Testvolumen
Privatkliniken	2,876	18.500 Tests
Spezialpraxen	1,124	12.750 Tests

Talis Biomedical Corporation (TLIS) – Geschäftsmodell: Kostenstruktur

Forschungs- und Entwicklungskosten

Für das Geschäftsjahr 2023 meldete die Talis Biomedical Corporation Forschungs- und Entwicklungskosten in Höhe von 24,3 Millionen US-Dollar.

Geschäftsjahr	F&E-Ausgaben	Prozentsatz des Gesamtumsatzes
2023	24,3 Millionen US-Dollar	68.5%
2022	19,7 Millionen US-Dollar	62.3%

Kosten für klinische Tests und Validierung

Die Ausgaben für klinische Tests und Validierung der Talis Biomedical Corporation beliefen sich im Jahr 2023 auf insgesamt etwa 12,5 Millionen US-Dollar.

• Validierung des COVID-19-Diagnosetests: 6,2 Millionen US-Dollar
• Panel-Tests auf Atemwegserreger: 4,3 Millionen US-Dollar
• Zusätzliche Investitionen in klinische Studien: 2 Millionen US-Dollar

Fertigungs- und Produktionsinvestitionen

Die Herstellungskosten für 2023 beliefen sich auf 15,8 Millionen US-Dollar, wobei der Schwerpunkt auf diagnostischen Testgeräten und der Reagenzienproduktion lag.

Kategorie „Fertigung“.	Kosten
Geräteherstellung	8,6 Millionen US-Dollar
Reagenzienproduktion	5,2 Millionen US-Dollar
Qualitätskontrolle	2 Millionen Dollar

Vertriebs- und Marketingausgaben

Die Vertriebs- und Marketingkosten der Talis Biomedical Corporation beliefen sich im Jahr 2023 auf 9,7 Millionen US-Dollar.

• Digitale Marketingkampagnen: 3,4 Millionen US-Dollar
• Vergütung des Vertriebsteams: 4,2 Millionen US-Dollar
• Teilnahme an Messen und Konferenzen: 2,1 Millionen US-Dollar

Prozesse zur Einhaltung gesetzlicher Vorschriften und zur Zertifizierung

Die Kosten für die Einhaltung gesetzlicher Vorschriften beliefen sich im Jahr 2023 auf 5,6 Millionen US-Dollar.

Compliance-Kategorie	Kosten
FDA-Zertifizierung	2,8 Millionen US-Dollar
CLIA-Zertifizierung	1,5 Millionen Dollar
Internationale behördliche Zulassungen	1,3 Millionen US-Dollar

Talis Biomedical Corporation (TLIS) – Geschäftsmodell: Einnahmequellen

Verkauf von COVID-19-Diagnosetestkits

Im vierten Quartal 2023 meldete Talis Biomedical einen Gesamtproduktumsatz von 4,1 Millionen US-Dollar, hauptsächlich aus dem Verkauf von COVID-19-Diagnosetestkits.

Produkttyp	Umsatz ($)	Marktsegment
COVID-19-Schnelltestkits	3,200,000	Gesundheitseinrichtungen
COVID-19 PCR-Testkits	900,000	Kliniken und Labore

Lizenzierung von Diagnosetechnologie

Talis Biomedical erwirtschaftete im Jahr 2023 Einnahmen aus Technologielizenzen in Höhe von 750.000 US-Dollar.

• Lizenzierung von Diagnoseplattformen an Hersteller medizinischer Geräte
• Lizenzierung molekularer Testtechnologie
• Lizenzvereinbarungen für geistiges Eigentum

Wiederkehrende Verkäufe an Gesundheitseinrichtungen

Die jährlichen wiederkehrenden Verkäufe an Gesundheitseinrichtungen beliefen sich im Jahr 2023 auf insgesamt 5,6 Millionen US-Dollar.

Institutionstyp	Jahresumsatz ($)	Vertragsdauer
Krankenhäuser	2,800,000	12-24 Monate
Forschungszentren	1,500,000	Jährliche Erneuerung
Privatkliniken	1,300,000	Vierteljährliche Vereinbarungen

Beratungs- und technische Supportdienste

Technischer Support und Beratungsdienste generierten im Jahr 2023 einen Umsatz von 650.000 US-Dollar.

• Schulung zur Durchführung diagnostischer Tests
• Technische Fehlerbehebungsdienste
• Beratung zu individuellen Diagnoselösungen

Mögliche staatliche und institutionelle Verträge

Ausstehende Regierungsvertragsverhandlungen im Wert von etwa 3,2 Millionen US-Dollar (Stand Januar 2024).

Vertragstyp	Potenzieller Wert ($)	Status
Vertrag des Bundesgesundheitsamtes	1,800,000	Wird überprüft
Staatlicher Vertrag über öffentliche Gesundheit	1,400,000	Verhandlungsphase

Talis Biomedical Corporation (TLIS) - Canvas Business Model: Value Propositions

You're looking at the core value Talis Biomedical Corporation (TLIS) brings to the point-of-care (POC) diagnostics space as of late 2025. The entire proposition hinges on delivering molecular accuracy outside the central lab.

Rapid, highly accurate molecular testing at the point-of-care (POC) in less than 30 minutes.

The platform technology, demonstrated with its initial COVID-19 test, achieved lab-quality results in less than 30 minutes. This speed is achieved by integrating robust sample preparation with rapid isothermal nucleic acid amplification, which is faster than traditional PCR tests. The system targets two genes (ORF1ab and N) for optimized sensitivity.

Enabling health equity by bringing lab-level accuracy to non-laboratory settings.

Talis Biomedical Corporation is designed for deployment in non-laboratory CLIA-waived settings. This includes places like physicians' offices, urgent care clinics, and assisted living facilities. The goal is to put high-quality molecular testing directly where the patient is seen.

Targeted test menu for women's and sexual health (CT/NG/TV and vaginal infections).

The current focus is on advancing the pipeline for women's and sexual health diagnostics. Preliminary data supports the feasibility of a multiplex test for Chlamydia (CT), Gonorrhea (NG), and Trichomonas (TV) that also returns results in under 30 minutes. Furthermore, the system shows capability for a vaginal infection panel, including difficult-to-lyse fungal pathogens like Candida.

Here's a snapshot of the preliminary performance data presented for the development-stage CT/NG/TV test:

Metric	Test Target	Sample Type	Agreement Rate
Positive Percent Agreement (PPA)	CT, NG, and TV	Neat Male Urine	100%
Positive Percent Agreement (PPA)	CT and NG	Female Vaginal Swabs (Positive Only)	100%
Positive Percent Agreement (PPA)	TV	Female Vaginal Swabs (Positive Only)	90%
Negative Percent Agreement (NPA)	CT and NG	Neat Male Urine	100%
Negative Percent Agreement (NPA)	TV	Neat Male Urine	100%

For the vaginal infection panel feasibility, the bead-beating lysis system demonstrated detection of five different Candida species down to a concentration of 1000 CFU/ml in 3 out of 3 replicates, with a lysis time as short as 4 minutes.

Simple, intuitive touch-screen interface for untrained users.

The Talis One integrated system is a compact, sample-to-answer solution. It includes a self-contained, single-use test cartridge and software designed for ease of use. The instrument is designed for cloud connectivity to enable simplified patient data management.

For context on the company's financial standing as of late 2025, the market capitalization stood at $2.91 Million USD as of December 2025. The stock price on December 03, 2025, was $1.60. The Price-To-Sales Ratio was calculated at 7.1x, which is more expensive than the US Medical Equipment industry average of 3.4x.

• The platform is a molecular diagnostic solution.
• It uses isothermal nucleic acid amplification technology.
• The system is designed for use in CLIA-waived settings.
• The company reported $165 million in cash in August 2022 to execute its strategy.

Talis Biomedical Corporation (TLIS) - Canvas Business Model: Customer Relationships

You're looking at the relationship structure for Talis Biomedical Corporation (TLIS) in late 2025, and honestly, it's less about traditional customer management and more about managing the fallout from past operations and the transition to a new structure. The focus has shifted dramatically.

Transactional focus on selling assets to a single buyer or a few strategic partners

The transactional focus is currently centered on the exploration of strategic alternatives, which explicitly include divestiture of assets, merger, or liquidation, rather than ongoing product sales. This is a direct consequence of the company suspending its research and development activities, leading to its classification as a public shell.

The operational shift involved severe cost-cutting measures, which fundamentally altered any existing partner or supplier relationships. Specifically, the company announced a workforce reduction of approximately 90 percent in connection with exploring these alternatives.

• Evaluating strategic alternatives announced in November 2023.
• Explicitly considering divestiture of assets as an option.
• Workforce reduction implemented was approximately 90 percent.
• Trading symbol TLIS was slated for delisting from Nasdaq.

Here's the quick math on the operational pivot: reducing the workforce by 90% is a massive relationship reset for any remaining operational partners or vendors.

Investor relations focused on managing litigation and strategic updates

Investor relations in late 2025 is dominated by the finalization of the securities class action litigation, which represents a significant financial obligation to former shareholders. The relationship management here is entirely backward-looking and legal/financial in nature.

The $32.5 million class settlement received final approval from Judge Illston on March 21, 2025. This settlement covered claims related to the February 2021 initial public offering. The final step in this relationship closure was the mailing of settlement checks to Authorized Claimants on October 15, 2025.

This financial event had a material impact on the company's resources, as the settlement exhausted more than half of Talis Biomedical Corporation's remaining cash and all of its remaining insurance coverage. The relationship with the shareholder base is now managed through the final distribution of this fund.

Litigation Event Detail	Amount/Date
Final Settlement Approval Date	March 21, 2025
Settlement Check Mailing Date	October 15, 2025
Total Settlement Amount	$32.5 million
Insurance Contribution (Approximate)	$5 million

Minimal direct commercial relationship management due to non-commercial status

Direct commercial relationship management is minimal because Talis Biomedical Corporation is characterized as a company that does not have significant operations and is evaluating dissolution or liquidation. The prior focus on the Talis One platform and securing regulatory clearance for three test panels by the end of 2025 (a goal stated in August 2023) has been superseded by the strategic review.

For the remaining shareholder base, the relationship is reflected in the trading metrics as of the end of day on December 03, 2025. The stock price was $1.60. The 52-week trading range for the stock was between a low of $1.04 and a high of $2.00. Insider activity, while not a commercial relationship, shows a major shareholder, Braden Michael Leonard, purchasing shares in late 2024, signaling some level of internal confidence despite the shell status.

• Current Stock Price (Dec 03, 2025): $1.60.
• 52-Week Stock Price Range: $1.04 to $2.00.
• Prior goal: Regulatory clearance for three test panels by end of 2025.
• Insider purchases by Braden Michael Leonard totaled $58,804.45 in the 24 months prior to September 2024.

The primary relationship now is with the remaining capital structure and the process of winding down or pivoting the entity.

Talis Biomedical Corporation (TLIS) - Canvas Business Model: Channels

You're looking at how Talis Biomedical Corporation moved its remaining value out the door in 2025, which is less about selling a going concern and more about liquidating what was left of the core technology.

Direct sales of corporate assets via auction or private sale process

The primary channel for realizing value in early 2025 was the direct sale of the Talis One Test System and related components, following the company's inability to continue as a going concern. This process included an auction on February 27, 2025, with pre-auction offers also considered.

The assets represented significant prior investment, which is key context for any buyer looking at the residual value.

Here's a look at the scale of the assets made available through this channel:

Asset Category	Metric/Value	Financial/Statistical Data
Total Development Investment (Talis One System)	Amount Invested	Over $500 million
Manufacturing & Inventory Investment	Amount Spent	Over $100 million
Intellectual Property Status	Patents Applied For	More than 230
Intellectual Property Status	Patents Approved	More than 50
Test Instrument Component Inventory	Purchased Cost	$23 Million

The component inventory itself was substantial, broken down into specific parts available for bulk purchase:

• More than 4,000 IDS Monochrome 6MP cameras.
• More than 4,500 IDS machine version cameras.
• Nearly 5,000 Mean Well power supplies.
• More than 4000 Sandisk 512GB microSD memory cards.

Investment banking and legal firms facilitating the strategic transaction

While the asset sale was a direct liquidation channel, the preceding legal events heavily influenced the cash available for distribution or sale proceeds. Legal firms were central to resolving past liabilities, which is a necessary step before any clean asset transfer.

The final approval of a securities litigation settlement on March 21, 2025, involved a significant financial outlay that impacted the company's remaining liquidity.

• Class Action Settlement Amount: $32.5 million.
• Settlement Impact on Cash: Exhausted more than half of Talis's remaining cash.
• Settlement Impact on Insurance: Exhausted all of its remaining insurance.
• Recovery for Plaintiffs (Maximum Estimated Damages): 20%

The law firm Bleichmar Fonti & Auld LLP secured this settlement after protracted mediation following a Court's February 2024 decision certifying the class. Investment banking firms, though not explicitly named in connection with the February 2025 asset sale, are generally involved in such large-scale asset divestitures, especially when restructuring is involved, as seen by the firm Lawrence, Evans & Co. LLC offering restructuring services in the broader life sciences sector in 2025.

Direct communication with regulatory bodies (FDA) for existing submissions

Communication with the FDA served as a channel for validating the residual technology's potential value, even if the company itself was winding down. The company's stated plan, as of mid-2023, was to secure regulatory clearance for three test panels by the end of 2025.

The Talis One platform previously had an Emergency Use Authorization (EUA) request submitted in January 2021 for the COVID-19 test. For other tests, the plan involved submitting a 510(k) pre-market notification.

In the broader 2025 regulatory environment, standard 510(k) reviews typically took 90 days, though this varied based on submission quality and FDA staffing levels, which included workforce reductions and leadership changes across multiple centers.

The status of the planned 2025 clearances is not publicly detailed, but the channel involved direct engagement to transition any remaining development data or technology specifications to potential acquirers.

Talis Biomedical Corporation (TLIS) - Canvas Business Model: Customer Segments

You're looking at the customer segments for Talis Biomedical Corporation (TLIS) as of late 2025, and honestly, the picture is dominated by financial and legal entities rather than end-users of diagnostic tests. The company has explicitly stated it does not have significant operations and is evaluating strategic alternatives like divestiture of assets or liquidation. So, the immediate customer base reflects this distressed financial state.

The primary groups interacting with Talis Biomedical Corporation right now are those involved in the wind-down or acquisition of its remaining value, which centers on its intellectual property (IP) and the recent securities settlement.

Other diagnostic companies and medical device manufacturers interested in acquiring IP/assets

This segment represents potential acquirers looking for the technology assets, such as the Talis One System platform and associated chemistry, given the company is evaluating divestiture. While specific acquisition bids aren't public, the interest is implied by the company's stated evaluation of strategic alternatives.

• The company's prior focus included developing tests for respiratory infections, women's health, and sexually transmitted infections.
• The Talis One System was designed as a compact, sample-to-answer, cloud-enabled, molecular diagnostic platform.

Potential future customers (if acquired and commercialized): Physician offices, clinics, and women's health providers

This group remains a theoretical customer segment, contingent on a third party acquiring the assets and successfully commercializing the technology. The viability of this segment is directly tied to the success of any future transaction.

• The technology was intended for point-of-care molecular testing.
• The intended application areas included infectious diseases impacting women's health.

Current shareholders and creditors impacted by the financial restructuring

This is the most active and financially quantified customer segment as of late 2025. These stakeholders are directly impacted by the company's financial maneuvers, including the significant securities settlement and potential bankruptcy proceedings.

Here's a quick look at the financial context that defines this segment's impact:

Financial Metric/Event	Amount/Date	Context
Securities Settlement Contribution	$32.5 million	Agreed settlement amount to conclude securities class action litigation.
Company Cash Portion of Settlement	$27.5 million	The amount to be paid from company cash reserves.
Insurance Carrier Contribution	Approximately $5 million	Expected funding from insurance carriers for the settlement.
Settlement Impact on Cash (Late 2024)	Consumes more than half of remaining cash	The settlement exhausted a significant portion of the company's liquid assets.
Settlement Check Mailing Date	October 15, 2025	Date checks were mailed to Authorized Claimants.
Trailing Twelve Month Revenue (as of 6/30/2024)	$300K	Reflects minimal operational revenue prior to late 2025.
Market Capitalization (as of 8/14/2024)	$7.31 million	Reflects the market's valuation of the equity stake.

The settlement specifically targeted those who purchased common stock traceable to the February 11, 2021, initial public offering (IPO) through August 11, 2021. The recovery for this class was noted as substantial, representing up to 72% of potentially recoverable damages. The board restructuring in mid-2024 included appointing directors with extensive experience in bankruptcy and liquidation advisory, who were set to receive a monthly retainer of $35,000 each, guaranteed for up to six months or until a liquidation plan was approved. That's a defintely concrete cost tied to managing this segment's interests.

Finance: draft 13-week cash view by Friday.

Talis Biomedical Corporation (TLIS) - Canvas Business Model: Cost Structure

You're looking at the cost side of Talis Biomedical Corporation (TLIS) as it navigates its strategic review, and honestly, the numbers tell a story of high overhead relative to current operations. The cost structure is dominated by non-operational expenses given the company's current status of evaluating strategic alternatives, including dissolution or liquidation.

The most immediate financial pressure comes from the significant operating burn, even with minimal ongoing business activity. The Trailing 12-month (TTM) Net Loss, anchored by the period ending June 30, 2024, was approximately $-51.0 million. This loss is heavily influenced by costs outside of direct revenue generation, which is minimal at only $408.00K in TTM revenue as of June 30, 2024.

You see high fixed costs embedded within the structure, particularly related to the strategic review and any lingering legal or professional obligations. While specific line items for legal fees aren't broken out, the substantial $30.9 million in Other Expenses dwarfs the small revenue base. Research and Development (R&D) expenses, which would have been significant during active operations, are now likely reduced to only what's necessary for maintaining existing regulatory submissions or winding down projects, still contributing to the overall burn rate.

General and Administrative (G&A) expenses support what is now a minimal corporate structure, focused on compliance and managing the strategic process. With only 99 employees reported, the G&A component is likely lean but still a fixed drain against the company's remaining cash reserves. The cost of revenue itself, at $20.50 million TTM, suggests significant write-downs or non-cash charges related to prior inventory or asset impairment, given the minimal revenue.

Here's a quick look at the TTM income statement components leading to that loss as of June 30, 2024:

Financial Metric	Amount (TTM ending June 30, 2024)
Revenue	$408.00K
Cost of Revenue	$20.50 million
Gross Profit	$-20.1 million
Other Expenses (Includes G&A, Legal, R&D components)	$30.9 million
Earnings (Net Loss/Pretax Income)	$-51.0 million

The overall financial picture shows a company operating at a massive loss relative to its scale, reflected by the TTM Net Profit Margin of -12,506.37%. The balance sheet shows total assets of $72.70 million against total liabilities of $8.20 million in the latest reported quarter. The market reflects this burn, with a Market Cap of only US$2.92 million as of December 2, 2025.

The key cost drivers that you need to monitor closely are:

• Other Expenses: At $30.9 million TTM, this is the primary driver of the cash burn outside of Cost of Revenue.
• Cost of Revenue: At $20.50 million TTM, this is disproportionately high compared to the $408.00K in revenue.
• Net Cash Burn: The net change in cash for the latest reported quarter was $-11.25 million.
• Debt Profile: The total debt-to-equity ratio stands at 38.66%.

Finance: draft 13-week cash view by Friday.

Talis Biomedical Corporation (TLIS) - Canvas Business Model: Revenue Streams

You're looking at the revenue side of Talis Biomedical Corporation (TLIS) as of late 2025, and honestly, the picture is dominated by its transition phase, not product sales.

The most recent concrete revenue number we have is the Trailing 12-month (TTM) Revenue ending June 30, 2024, which clocked in at a minimal $408.00K. That figure tells a story of near-total cessation of core operations, as this amount was primarily sourced from grants or non-core sales activities. To be fair, this represented a steep drop, down -85.69% year-over-year from the prior period's annual revenue of $2.13M in 2023.

Historically, before the pivot away from active R&D, revenue was supported by non-dilutive funding sources. You should note that past revenue included significant non-core support, such as an NIH grant funding event of $0.5 million recorded in Q2 2023. This type of funding is definitely not sustainable as a primary revenue stream for a commercial entity, but it was a key component of the cash runway.

When assessing potential one-time revenue, the most significant recent financial event wasn't an IP sale, but rather a major litigation settlement. Talis Biomedical entered into a settlement agreement dated August 29, 2024, to resolve securities class action litigation related to its February 2021 initial public offering (IPO). The total settlement contribution is $32.5 million. Here's the quick math on that: the company's insurance carriers were expected to fund about $5 million, leaving the remaining $27.5 million to be paid from the company's cash reserves. What this estimate hides is the immediate impact on the balance sheet, as that cash outflow was a critical, non-recurring event.

Given the company's status as a 'public shell' due to suspended research and development activities, the current revenue generation is extremely limited, making these historical and one-time figures the most relevant data points for understanding past cash inflows.

Here is a snapshot of the key financial figures related to Talis Biomedical Corporation's recent revenue and financial events:

Metric	Amount	Period/Context
TTM Revenue	$408.00K	Twelve months ending June 30, 2024
Annual Revenue (2023)	$2.13M	Year 2023
NIH Grant Funding (Past)	$0.5 million	Q2 2023 [as provided in outline]
Securities Litigation Settlement	$32.5 million	Settlement contribution dated August 29, 2024
Settlement Paid from Cash Reserves	$27.5 million	Portion of settlement funded by company cash

The revenue streams, as they stood near the end of 2025, can be summarized by the nature of these inflows:

• Minimal TTM revenue from grants or non-core sales.
• Past reliance on NIH grant funding sources.
• Significant, non-recurring cash event from litigation settlement.
• Current revenue generation is effectively near zero from core operations.

Finance: draft 13-week cash view by Friday.